Vivos Therapeutics Receives “Hold” Rating as Analysts Weigh In

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has garnered an average recommendation of “Hold” from five brokerage firms monitoring the company, according to data from MarketBeat.com. One analyst has issued a sell rating, while two analysts have given the stock a hold rating and two have rated it as a buy. The consensus twelve-month target price among analysts stands at approximately $4.92.

In recent evaluations, several research analysts have provided insights into Vivos Therapeutics. On December 1, 2023, Zacks Research upgraded the company’s rating from “strong sell” to “hold.” Meanwhile, Ascendiant Capital Markets lowered its target price for Vivos Therapeutics from $6.50 to $5.50 while maintaining a buy rating in a note released on December 3, 2023. Weiss Ratings reiterated a “sell (e+)” rating on October 8, 2023. Additionally, HC Wainwright initiated coverage on the company on November 17, 2023, assigning a buy rating with a price target of $7.00.

The stock opened at $2.06 on Tuesday, reflecting a decline of 7.2%. Over the past year, Vivos Therapeutics has experienced a low of $1.92 and a high of $7.95. The company’s 50-day moving average is $2.21, while its 200-day moving average is $3.43. With a market capitalization of $18.52 million, Vivos Therapeutics has a price-to-earnings ratio of -1.16 and a beta of 6.89. Its quick ratio and current ratio both stand at 0.78, and the debt-to-equity ratio is 3.31.

Recent Financial Performance

Vivos Therapeutics reported its quarterly earnings on November 19, 2023. The company disclosed earnings per share (EPS) of ($0.49), surpassing analysts’ consensus estimate of ($0.53) by $0.04. Revenue for the quarter reached $6.78 million, significantly above expectations of $4.49 million. Despite these figures, Vivos Therapeutics recorded a negative return on equity of 351.28% and a negative net margin of 98.77%. Analysts predict that the company will report an EPS of ($1.79) for the current fiscal year.

About Vivos Therapeutics

Vivos Therapeutics, Inc. specializes in medical technology, focusing on the development and commercialization of oral appliance therapies aimed at treating obstructive sleep apnea (OSA) and other airway-related disorders. Its proprietary Vivos System combines clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to offer non-surgical, non-invasive solutions for mild to moderate sleep-disordered breathing. The system includes a variety of custom oral devices, digital workflow tools, and a structured treatment protocol.

Market observers will continue to monitor Vivos Therapeutics as analysts refine their forecasts and the company navigates its financial landscape.